Back to discover
Drug

Sufentanil citrate

Approved · FDA / EMA
Late-stage development
Also known as Sufenta, Fentathienil citrate, Sufentanyl citrate, Sulfentanil citrate+2 more

Sufenta, Fentathienil citrate, Sufentanyl citrate, Sulfentanil citrate, Sulphentanil citrate, sufentanil (as citrate).

4
Active clinical trials
11
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Whether Opioids Are Factor That Induced Postoperative Delirium?

Clinical trial2020-12-31Completed · ClinicalTrials.gov

Approval: Dzuveo (EMA)

Regulatory2018-06-25EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Sufentanil citrate
Aliases & brands
SufentaFentathienil citrateSufentanyl citrateSulfentanil citrateSulphentanil citratesufentanil (as citrate)
RxNorm CUI
58964
Regulatory jurisdictions
emafda

Regulatory timeline

11 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
1996-12-11
Latest approval
2018-06-25
Authorities
FDA · EMA
Total events
11
fdaU.S. Food and Drug Administration· 10 events
2026-06-25Label change
Label change: SUFENTANIL CITRATE (ANDA074534)
Evidence ↗
2024-08-22Label change
Label change: SUFENTANIL CITRATE (ANDA074534)
Evidence ↗
2024-01-26Label change
Label change: SUFENTANIL CITRATE (ANDA074534)
Evidence ↗
emaEuropean Medicines Agency· 1 event
2018-06-25Approval
Approval: Dzuveo (EMA)

Indication: Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
LATEST COMPLETION 2023
4
Active studies
4
Recruiting
7
Late-stage (III+)
3
Completed
PHASE DISTRIBUTIONn = 7
Phase 31Phase 43Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.